News

Fierce Pharma2h
AstraZeneca touts early Ultomiris survival data in children living with rare post-transplant complication
Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...
AstraZeneca slips Monday, underperforms market
AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.
Business Weekly50m
AstraZeneca takes spending on novel China projects to around $8bn
Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...
PMLive5h
AstraZeneca and CSPC Pharmaceuticals enter AI-driven partnership worth $5.3bn
AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...
The Pharma Letter7h
AstraZeneca’s Ultomiris shows strong OS in HSCT TMA
Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...
Explore more
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer
AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...
BioPharma Dive3d
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...